Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside

Abstract

This article is an update on the clinical and research data available on systemic lupus erythematosus (SLE) and intravenous immunoglobulin (IVIg) therapy that includes some studies performed under the umbrella of the European Working Party on SLE. Various mechanisms of IVIg may play a role, some synergistically, in the modulation of SLE. Recently it has been suggested that IVIg also suppresses the expansion of autoreactive B lymphocytes through signalling of the FcgRIIB, idiotype-mediated inhibition of B cell receptors and neutralisation of cytokines such as the B cell survival factors (B cell activation factor (BAFF and APRIL). In case reports and in open trials, high-dose IVIg (2 g/kg over a 5-day period) has consistently been shown to be a beneficial and safe adjunct therapeutic agent for over 20 manifestations in patients with SLE. It can be given as a first choice of therapy in some cases, for example, in neurological involvement and in those patients who refuse certain immunosuppressive agents such as cyclophosphamide, or in patients who have concomitant infections. Furthermore, IVIg may have a steroid-sparing effect although this characteristic needs further investigation. Specific IVIg (an anti-idiotype to anti-DNA, phosphorylcholine and antiphospholipids) has been shown to be effective in experimental murine models. Hence, extractable IVIg that is directed to the specific pathogenic immunoglobulins will enable the more specific therapy for patients with lupus.

Keywords

intravenous immunoglobulins IVIg systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

1 Kazatchkine MD Kaveri SV . Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747–755.

2 Shoenfeld Y Katz U . IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity 2005; 38: 123–137.

3 Sapir T Blank M Shoenfeld Y . Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann N Y Acad Sci 2005; 1051: 743–778.

4 Le Pottier L Sapir T Bendaoud B Youinou P Shoenfeld Y Pers JO . Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann N Y Acad Sci 2007; 1110: 426–432.

5 Sherer Y Shoenfeld Y . Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus. Autoimmun Rev 2006; 5: 153–155.

6 Bussone, G, Dib, H, Dimitrov, JD, et al. Identification of target antigens of self-reactive IgG in intravenous immunoglobulin preparations. Proteomics 2009; 9: 2253–2262.

7 Kaneko Y Nimmerjahn F Ravetch JV . Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313: 670–673.

8 Kaveri SV Lacroix-Desmazes S Bayry J . The antiinflammatory IgG. N Engl J Med 2008; 359: 307–309.

9 Vani J Elluru S Negi VS . Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev 2008; 7: 440–444.

10.

10 Caccavo D Vaccaro F Ferri GM Amoroso A Bonomo L . Anti-idiotypes against antiphospholipid antibodies are present in normal polyspecific immunoglobulins for therapeutic use. J Autoimmun 1994; 7: 537–548.

11.

11 DeKeyser F DeKeyser H Kazatchkine MD Rossi F Dang H Talal N . Pooled human immunoglobulins contain anti-idiotypes with reactivity against the SLE-associated 4B4 cross-reactive idiotype. Clin Exp Rheumatol 1996; 14: 587–591.

12.

12 Silvestris F Cafforio P Dammacco F . Pathogenic anti-DNA idiotype-reactive IgG in intravenous immunoglobulin preparations. Clin Exp Immunol 1994; 97: 19–25.

13.

13 Blank M Manosroi J Tomer Y . Suppression of experimental systemic lupus erythematosus (SLE) with specific anti-idiotypic antibody-saporin conjugate. Clin Exp Immunol 1994; 98: 434–441.

14.

14 Shoenfeld Y Rauova L Gilburd B . Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 2002; 14: 1303–1311.

15.

15 Blank M Anafi L Zandman-Goddard G . The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol 2007; 19: 857–865.

16.

16 Su J Georgiades A Wu R Thulin T de Faire U Frostegard J . Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 2006; 188: 160–166.

17.

17 Krause I Blank M Sherer Y Gilburd B Kvapil F Shoenfeld Y . Induction of oral tolerance in experimental antiphospholipid syndrome by feeding with polyclonal immunoglobulins. Eur J Immunol 2002; 32: 3414–3424.

18.

18 Faria-Neto JR Chyu KY Li X . Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis 2006; 189: 83–90.

19.

19 Harnett W . harnett, MM. Phosphorylcholine: friend or foe of the immune system. Immunol Today 1999; 20: 125–129.

20.

20 Brown M Schiffman G Rittenberg MB . Subpopulations of antibodies to phosphocholine in human serum. J Immunol 1984; 132: 1323–1328.

21.

21 Su J Hua X Concha H Svenungsson E Cederholm A Frostegård J . Natural antibodies against phosphorylcholine as potential protective factors in SLE. Rheumatology (Oxford) 2008; 47: 1144–1150.

22.

22 Albert H Collin M Dudziak D Ravetch JV Nimmerjahn F . In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc Natl Acad Sci U S A. 2008; 105: 15005–15009.

23.

23 Levy Y Sherer Y Ahmed A . A study of 20 SLE patients with intravenous immunoglobulin-clinical and serological response. Lupus 1999; 8: 705–712.

24.

24 Zandman-Goddard G Levy Y Shoenfeld Y . Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol 2005; 29: 219–228.

25.

25 Orbach H Tishler M Shoenfeld Y . Intravenous immunoglobulin and the kidney- a two-edged sword. Semin Arthritis Rheum 2004; 34: 593–601.

26.

26 Zandman-Goddard G Shoenfeld Y . Infections and SLE. Autoimmunity 2005; 38: 473–485.

27.

27 Sherer Y Kuechler S Scali JJ . Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. IMAJ 2008; 10: 55–57.

28.

28 Katz U Achiron A Sherer Y Shoenfeld Y . Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007; 6: 257–259.

29.

29 Zandman-Goddard G Krauthammer A Shoenfeld Y . The steroid-sparing effect of IVIG. Expert Rev Clin Immunol 2007; 3: 773–780.